The last of a total of 972 patients have now been enrolled and treated in the company’s ongoing European phase III trial (CIRCUS).

In the trial, half of patients received the company’s pharmaceutical CicloMulsion for treating reperfusion injury coincident with myocardial infarction. “We’ve now reached a major milestone in the European cardiac study on NeuroVive’s product CicloMulsion®. The final patient was enrolled and treated in the study on 16 February, and the trial will now be followed up for a one-year period, as it finally closes for data analysis. Enrolment of patients to the trial went well, and we’re satisfied with how it has followed our original plan so far,” commented NeuroVive’s CEO Mikael Brönnegård in a press release.